# Top 10 Application Domains for BIP Control Theory
## Ranked by Feasibility, Impact, and Fit

---

## Ranking Methodology

Each domain scored on:
- **Fit** (1-10): How well does BIP framework match domain characteristics?
- **Impact** (1-10): How valuable would success be?
- **Feasibility** (1-10): How practical is near-term deployment?
- **Total Score** = Fit + Impact + Feasibility (max 30)

---

## 1. Tokamak Plasma Density Control (FUSION)
**Total Score: 28/30** (Fit: 10, Impact: 10, Feasibility: 8)

### Why Perfect Fit:

**Hard physical constraints:**
- Greenwald limit: n̄ < n_G (disruption if violated)
- β limit: pressure can't exceed critical value
- Current limits: q > 2 for stability

**Measurable observables (Ψ):**
- Interferometry: n̄ in real-time (1 kHz)
- Magnetics: I_p, β_N (10 kHz)
- ECE: T_e profile (10 kHz)
- MSE: current profile (1 kHz)

**Real-time requirements:**
- MHD timescale: 1-10 ms
- Need <1 ms control decisions
- Disruptions cost millions

**Regime boundaries (stratification):**
- L-mode ↔ H-mode transitions
- ELM-free ↔ ELMy H-mode
- Attached ↔ detached divertor

**Transfer learning:**
- DIII-D → ITER via dimensionless scaling
- JET → SPARC (Commonwealth Fusion)

### Pros:

✅ **Perfect mathematical fit**: All BIP components map naturally  
✅ **High stakes**: Disruptions catastrophic ($millions damage)  
✅ **Existing baselines**: Can compare to PID, MPC, DeepMind RL  
✅ **Validation path**: PPPL, DIII-D, GA willing to collaborate  
✅ **Massive funding**: ITER ($20B), Commonwealth ($2B), TAE ($1B+)  
✅ **Nobel potential**: If fusion succeeds, foundational work recognized  

### Cons:

⚠️ **Complex physics**: Turbulence, edge physics not fully understood  
⚠️ **Sparse diagnostics**: Can't measure everything (Ψ incomplete)  
⚠️ **Long timelines**: ITER first plasma 2025+, Q>10 by 2035+  
⚠️ **Competition**: DeepMind, ITER consortium, many teams  

### Deployment Pathway:

**Year 1-2**: Simulation validation (TRANSP, OMFIT codes)  
**Year 2-3**: Historical data testing (DIII-D, JET archives)  
**Year 3-5**: Real-time deployment (DIII-D live experiments)  
**Year 5-10**: ITER integration, commercial fusion (Commonwealth)  

### Market Size: $10B+ (fusion R&D globally)

---

## 2. Chemical Process Control (BATCH REACTORS)
**Total Score: 27/30** (Fit: 9, Impact: 9, Feasibility: 9)

### Why Excellent Fit:

**Hard constraints:**
- Temperature limits: T < T_runaway (exothermic reactions)
- Pressure limits: P < P_vessel_rated (explosion risk)
- Concentration limits: [X] in safe range (toxicity, flammability)
- pH limits: pH ∈ [safe_min, safe_max]

**Measurable observables:**
- Temperature sensors (RTDs, thermocouples) at 1-10 Hz
- Pressure transducers at 10-100 Hz
- Flow meters (mass, volumetric) at 1-10 Hz
- Concentration (spectroscopy, chromatography) at 0.1-1 Hz

**Real-time requirements:**
- Thermal runaway timescale: seconds to minutes
- Need sub-second control response
- Violations can cause explosions, toxic releases

**Regime boundaries:**
- Batch start → steady mixing
- Exothermic onset → reaction plateau
- Batch end → product separation

**Transfer learning:**
- Lab-scale → pilot → industrial (scale-invariant if dimensionless)
- Reactor A → Reactor B (same chemistry, different geometry)

### Pros:

✅ **Mature diagnostics**: Chemical industry has good sensors  
✅ **High safety value**: Prevents disasters (Bhopal-type incidents)  
✅ **Immediate market**: $100B+ chemical manufacturing industry  
✅ **Regulatory driver**: EPA, OSHA require safety systems  
✅ **Existing baseline**: DCS (Distributed Control Systems) are standard  
✅ **Fast validation**: Can test on lab-scale reactors in months  

### Cons:

⚠️ **Reaction kinetics complex**: Non-linear, multi-phase, uncertain models  
⚠️ **Ψ-completeness hard**: Mixing, local hotspots hard to measure  
⚠️ **Industry conservative**: Slow to adopt new methods (proven = 10+ years)  
⚠️ **Heterogeneous systems**: Each plant is custom (less transfer learning)  

### Deployment Pathway:

**Year 1**: Lab-scale batch reactor (university or pilot plant)  
**Year 2**: Validate vs existing DCS on real batches  
**Year 3**: Industry pilot (pharma or specialty chemicals)  
**Year 4-5**: Regulatory approval, scale to production  
**Year 5+**: Licensing to control vendors (Honeywell, Emerson, ABB)  

### Market Size: $5B+ (process control systems)

---

## 3. Power Grid Frequency Stabilization
**Total Score: 26/30** (Fit: 9, Impact: 10, Feasibility: 7)

### Why Strong Fit:

**Hard constraints:**
- Frequency: f ∈ [59.95, 60.05] Hz (North America) - tight!
- Voltage: V ∈ [acceptable range] (grid stability)
- Line loading: I < I_max (transmission line thermal limits)
- Power balance: P_generation = P_load + P_losses

**Measurable observables:**
- Phasor Measurement Units (PMUs): 30-120 Hz sampling
- Frequency deviation: Δf in real-time
- Line currents, voltages: SCADA at 1-10 Hz
- Generator outputs: direct telemetry

**Real-time requirements:**
- Frequency deviation timescale: 100 ms - 10 s
- Need <100 ms control response
- Cascading failures can black out regions

**Regime boundaries:**
- Normal operation ↔ contingency (line trip)
- Stable ↔ unstable oscillations
- Synchronous ↔ islanded operation

**Transfer learning:**
- Grid topology changes (dimensionless power flow equations)
- Summer ↔ winter load patterns
- Different utility companies (physics is same)

### Pros:

✅ **Critical infrastructure**: Blackouts cost billions, affect millions  
✅ **Excellent observability**: PMUs provide rich data (Ψ complete)  
✅ **Fast dynamics**: Real-time control essential (BIP advantage)  
✅ **Renewables integration**: Variable sources need smart control  
✅ **Regulatory support**: FERC, NERC mandate stability  
✅ **Large market**: $10B+ grid control/automation  

### Cons:

⚠️ **Legacy systems**: Replacing existing SCADA/EMS is hard  
⚠️ **Distributed control**: Multi-operator coordination complex  
⚠️ **Cybersecurity**: Grid control is critical infrastructure (attack surface)  
⚠️ **Politics**: Utilities move slowly, regulatory approval takes years  

### Deployment Pathway:

**Year 1-2**: Simulation (PowerWorld, PSSE grid simulators)  
**Year 2-3**: Test on microgrid testbed (university or DOE lab)  
**Year 3-5**: Pilot with progressive utility (e.g., ERCOT, CAISO)  
**Year 5-10**: FERC/NERC approval, wide deployment  

### Market Size: $10B+ (grid modernization)

---

## 4. Autonomous Vehicle Safety (COLLISION AVOIDANCE)
**Total Score: 25/30** (Fit: 8, Impact: 10, Feasibility: 7)

### Why Good Fit:

**Hard constraints:**
- Collision avoidance: d_obstacle > d_safe (no crashes)
- Lane boundaries: x ∈ lane_width
- Speed limits: v ≤ v_max
- Deceleration: a > a_min (passenger comfort)
- Time-to-collision: TTC > TTC_min

**Measurable observables:**
- LIDAR: 3D point clouds at 10-20 Hz
- Radar: velocity, range at 10-100 Hz
- Cameras: object detection at 30 Hz
- IMU: acceleration, orientation at 100-1000 Hz
- GPS/GNSS: position at 1-10 Hz

**Real-time requirements:**
- Collision timescale: 100 ms - 2 s
- Need <50 ms decision latency
- Human lives at stake

**Regime boundaries:**
- Highway ↔ urban ↔ parking (different strategies)
- Clear weather ↔ rain/snow (sensor degradation)
- Normal traffic ↔ emergency (accident ahead)

**Transfer learning:**
- Vehicle A → Vehicle B (same physics, different sensors)
- City A → City B (same traffic rules)
- Simulation → real-world (sim-to-real)

### Pros:

✅ **Massive impact**: 1.3M deaths/year globally (prevent accidents)  
✅ **Huge market**: $100B+ autonomous vehicle industry  
✅ **Fast iteration**: Can test in simulation extensively  
✅ **Regulatory momentum**: NHTSA, EU pushing safety standards  
✅ **Sensor rich**: Modern AVs have excellent observability  
✅ **Industry interest**: Waymo, Tesla, Cruise would care  

### Cons:

⚠️ **Uncertainty**: Pedestrian behavior, other drivers unpredictable  
⚠️ **Ψ-completeness**: Can't measure intent (what will that car do?)  
⚠️ **Edge cases**: Long tail of rare scenarios (deer, construction, etc.)  
⚠️ **Liability**: Who's responsible if BIP control fails?  
⚠️ **Real-world complexity**: Weather, occlusion, sensor failures  

### Deployment Pathway:

**Year 1-2**: Simulation (CARLA, LGSVL, custom scenarios)  
**Year 2-3**: Closed-track testing (proving grounds)  
**Year 3-5**: Public road testing (limited routes)  
**Year 5-10**: Regulatory approval, fleet deployment  

### Market Size: $100B+ (AV market)

---

## 5. Spacecraft Attitude Control (SATELLITES)
**Total Score: 26/30** (Fit: 9, Impact: 8, Feasibility: 9)

### Why Strong Fit:

**Hard constraints:**
- Fuel limits: Δv_total < Δv_available (can't refuel)
- Solar panel pointing: angle to sun ∈ [acceptable for power]
- Thermal limits: T_components ∈ [safe range]
- Collision avoidance: d_debris > d_safe
- Communication windows: antenna pointing accuracy

**Measurable observables:**
- Star trackers: attitude at 1-10 Hz (very accurate)
- IMU/gyros: angular rates at 100-1000 Hz
- GPS: position at 1-10 Hz
- Magnetometers: magnetic field at 1-100 Hz
- Sun sensors: solar angle at 1-10 Hz

**Real-time requirements:**
- Attitude perturbations: seconds to minutes
- Need <1 s control response
- Fuel is precious (non-renewable)

**Regime boundaries:**
- Detumbling ↔ nominal operations
- Eclipse ↔ sunlight (power availability)
- Communication window ↔ silent period

**Transfer learning:**
- Satellite A → Satellite B (same orbital mechanics)
- LEO → GEO (different perturbations, same physics)
- Simulation → flight (excellent sim-to-real in space)

### Pros:

✅ **Well-defined physics**: Orbital mechanics is deterministic  
✅ **Excellent sensors**: Star trackers, gyros are highly accurate  
✅ **High value**: Satellites cost $50M-$500M each  
✅ **Fast validation**: Can test in hardware-in-loop simulation  
✅ **Industry maturity**: Space industry adopts proven tech  
✅ **Fuel efficiency**: BIP could extend mission life (save fuel)  

### Cons:

⚠️ **Long timescales**: Launch to orbit takes years (slow iteration)  
⚠️ **Radiation**: Space environment harsh (hardware failures)  
⚠️ **Conservative industry**: Space is risk-averse (proven = decades)  
⚠️ **Lower urgency**: Existing control (PID, LQR) works well enough  

### Deployment Pathway:

**Year 1-2**: Simulation (STK, MATLAB/Simulink orbital sim)  
**Year 2-3**: Hardware-in-loop (air bearing testbed)  
**Year 3-5**: CubeSat demonstration mission  
**Year 5-10**: Operational satellite (commercial or gov't)  

### Market Size: $10B+ (satellite control systems)

---

## 6. Anesthesia Delivery (MEDICAL DEVICES)
**Total Score: 24/30** (Fit: 8, Impact: 9, Feasibility: 7)

### Why Good Fit:

**Hard constraints:**
- Blood pressure: BP ∈ [safe range] (hypotension kills)
- Oxygen saturation: SpO2 > 90% (brain damage if lower)
- Heart rate: HR ∈ [safe range]
- Anesthetic depth: BIS ∈ [40, 60] (too deep = overdose, too light = awareness)
- Drug dosage limits: total < max_safe_dose

**Measurable observables:**
- ECG: heart rate at 250-500 Hz
- Pulse oximetry: SpO2 at 1-10 Hz
- Blood pressure cuff: BP at 0.05-1 Hz (or continuous arterial line)
- BIS monitor: anesthetic depth at 1 Hz
- Capnography: CO2 at 10-50 Hz

**Real-time requirements:**
- Blood pressure crash: seconds to minutes
- Need <10 s control response
- Human lives at stake

**Regime boundaries:**
- Induction ↔ maintenance ↔ emergence
- Healthy patient ↔ compromised (cardiac, respiratory issues)
- Minor surgery ↔ major trauma

**Transfer learning:**
- Patient A → Patient B (age, weight, comorbidities scaled)
- Surgery A → Surgery B (same drugs, different procedures)
- Hospital A → Hospital B (same physiology)

### Pros:

✅ **High impact**: 300M surgeries/year globally (prevent deaths)  
✅ **Mature sensors**: Medical devices have excellent monitoring  
✅ **Clear constraints**: FDA defines safety limits precisely  
✅ **Existing automation**: TCI (Target Controlled Infusion) is baseline  
✅ **Revenue potential**: Medical device market $50B+  
✅ **Regulatory path**: FDA 510(k) if similar to existing devices  

### Cons:

⚠️ **Patient variability**: Pharmacokinetics differ wildly between patients  
⚠️ **Ψ-completeness**: Can't measure brain drug concentration directly  
⚠️ **Liability**: Medical malpractice lawsuits if control fails  
⚠️ **Ethics**: Doctors won't fully trust automated anesthesia (yet)  
⚠️ **Regulatory**: FDA approval takes 3-7 years, very expensive  

### Deployment Pathway:

**Year 1-2**: Simulation (pharmacokinetic/pharmacodynamic models)  
**Year 2-3**: Animal studies (regulatory requirement)  
**Year 3-5**: Human clinical trials (Phase I, II, III)  
**Year 5-10**: FDA approval, hospital adoption  

### Market Size: $5B+ (anesthesia equipment)

---

## 7. Building HVAC Optimization (ENERGY MANAGEMENT)
**Total Score: 23/30** (Fit: 7, Impact: 8, Feasibility: 8)

### Why Decent Fit:

**Hard constraints:**
- Temperature comfort: T ∈ [68°F, 74°F] (occupant comfort)
- Humidity: RH ∈ [30%, 60%] (mold prevention, comfort)
- CO2 levels: [CO2] < 1000 ppm (ASHRAE standard)
- Power limits: P_HVAC < P_max (demand charges)
- Equipment limits: chiller COP, boiler efficiency

**Measurable observables:**
- Temperature sensors: 0.1-1 Hz (cheap, ubiquitous)
- Humidity sensors: 0.1-1 Hz
- CO2 sensors: 0.01-0.1 Hz
- Occupancy sensors: 0.1-1 Hz (motion, camera)
- Power meters: 1-10 Hz

**Real-time requirements:**
- Building thermal mass: minutes to hours
- Need <1 minute control response (not critical)
- Energy costs accumulate (not life-threatening)

**Regime boundaries:**
- Occupied ↔ unoccupied (different setpoints)
- Summer ↔ winter (heating vs cooling)
- Peak demand ↔ off-peak (electricity pricing)

**Transfer learning:**
- Building A → Building B (same climate zone)
- Floor A → Floor B (same building, different use)
- Summer → winter (seasonal patterns)

### Pros:

✅ **Large market**: $100B+ building automation globally  
✅ **Energy impact**: Buildings use 40% of global energy  
✅ **Fast iteration**: Can test on real buildings in weeks  
✅ **Scalability**: Millions of buildings (huge deployment)  
✅ **ROI clear**: Energy savings pay for system in 2-5 years  
✅ **Low risk**: Comfort issues non-catastrophic  

### Cons:

⚠️ **Weak fit**: Constraints are "soft" not "hard" (comfort, not safety)  
⚠️ **Slow dynamics**: Hours timescale (BIP advantage unclear)  
⚠️ **Existing solutions**: Model-predictive HVAC works well already  
⚠️ **Low urgency**: Energy waste bad but not dangerous  
⚠️ **Commoditization**: HVAC control is competitive, low-margin  

### Deployment Pathway:

**Year 1**: Simulation (EnergyPlus building thermal model)  
**Year 2**: Single building deployment (university, office)  
**Year 3**: Multi-building portfolio (building operator)  
**Year 4-5**: Integration with BMS vendors (Honeywell, JCI, Siemens)  

### Market Size: $10B+ (building automation)

---

## 8. Robotic Manipulation (MANUFACTURING)
**Total Score: 24/30** (Fit: 8, Impact: 8, Feasibility: 8)

### Why Good Fit:

**Hard constraints:**
- Collision avoidance: d_human > d_safe (ISO safety standards)
- Force limits: F_contact < F_injury (collaborative robots)
- Workspace bounds: x ∈ [safe zone]
- Joint limits: θ ∈ [θ_min, θ_max]
- Tool path accuracy: |x_actual - x_desired| < tolerance

**Measurable observables:**
- Joint encoders: position at 1-10 kHz
- Force/torque sensors: 1-10 kHz
- Vision (cameras): 30-120 Hz
- LIDAR/depth: 10-30 Hz
- IMU on end-effector: 100-1000 Hz

**Real-time requirements:**
- Contact detection: milliseconds
- Need <10 ms control loop
- Human safety critical (ISO 10218, ISO/TS 15066)

**Regime boundaries:**
- Free motion ↔ contact (different control laws)
- High speed ↔ precision (speed/accuracy tradeoff)
- Autonomous ↔ human-in-loop (collaborative)

**Transfer learning:**
- Robot A → Robot B (kinematics differ, dynamics similar)
- Task A → Task B (pick-and-place → assembly)
- Factory A → Factory B (same manufacturing process)

### Pros:

✅ **Safety critical**: Human-robot collaboration needs formal guarantees  
✅ **Fast dynamics**: Millisecond control (BIP strength)  
✅ **Good sensors**: Industrial robots well-instrumented  
✅ **Large market**: $50B+ industrial robotics  
✅ **Validation path**: Can test on robot arms easily (abundant hardware)  
✅ **Industry adoption**: Manufacturing willing to try new control  

### Cons:

⚠️ **Existing methods**: Impedance control, admittance control work well  
⚠️ **Complex tasks**: Dexterous manipulation is hard (not just control)  
⚠️ **Ψ-completeness**: Contact geometry, friction hard to measure  
⚠️ **Model uncertainty**: Payload, environment vary  

### Deployment Pathway:

**Year 1**: Simulation (Gazebo, PyBullet, MuJoCo)  
**Year 2**: Lab robot (UR5, Franka Emika Panda)  
**Year 3**: Manufacturing pilot (automotive, electronics assembly)  
**Year 4-5**: Productization (ABB, KUKA, Fanuc integration)  

### Market Size: $50B+ (industrial robotics)

---

## 9. Insulin Pump Control (ARTIFICIAL PANCREAS)
**Total Score: 25/30** (Fit: 9, Impact: 9, Feasibility: 7)

### Why Strong Fit:

**Hard constraints:**
- Hypoglycemia: glucose > 70 mg/dL (seizures, coma if lower)
- Hyperglycemia: glucose < 180 mg/dL (long-term damage if higher)
- Insulin delivery limits: rate < max_safe_rate (overdose prevention)
- Time-in-range: glucose ∈ [70, 180] for >70% of time

**Measurable observables:**
- Continuous glucose monitor (CGM): every 5 minutes
- Meal announcements: user input (carbs)
- Activity tracking: accelerometer (exercise affects glucose)
- Insulin on board: calculated from delivery history

**Real-time requirements:**
- Glucose dynamics: minutes to hours
- Need <5 minute control update
- Life-threatening if wrong (hypo can kill in hours)

**Regime boundaries:**
- Fasting ↔ post-meal (different insulin sensitivity)
- Resting ↔ exercise (glucose uptake changes)
- Day ↔ night (dawn phenomenon)

**Transfer learning:**
- Patient A → Patient B (insulin sensitivity varies but patterns similar)
- Winter → summer (seasonal activity changes)
- Teenager → adult (physiology changes with age)

### Pros:

✅ **Clear constraints**: Hypo/hyperglycemia are well-defined  
✅ **High impact**: 500M diabetics globally (prevent complications)  
✅ **Excellent sensor**: CGMs are accurate, real-time  
✅ **Existing market**: $20B+ diabetes devices  
✅ **FDA pathway**: Artificial pancreas category established  
✅ **Patient need**: Manual insulin dosing is burdensome  

### Cons:

⚠️ **Meal uncertainty**: Carb counting is inaccurate (Ψ incomplete)  
⚠️ **Patient variability**: Insulin sensitivity varies 10× between patients  
⚠️ **Regulatory**: FDA approval takes 5-10 years, very rigorous  
⚠️ **Liability**: Death from hypoglycemia → massive lawsuits  
⚠️ **Competition**: Medtronic, Tandem, Insulet have working systems  

### Deployment Pathway:

**Year 1-2**: Simulation (UVA/Padova T1D simulator)  
**Year 2-3**: In-clinic studies (overnight, supervised)  
**Year 3-5**: Outpatient trials (home use, monitored)  
**Year 5-10**: FDA approval (PMA pathway), commercial launch  

### Market Size: $20B+ (diabetes devices)

---

## 10. High-Frequency Trading (FINANCIAL MARKETS)
**Total Score: 22/30** (Fit: 7, Impact: 7, Feasibility: 8)

### Why Moderate Fit:

**Hard constraints:**
- Position limits: |position| < max_position (risk management)
- Value-at-Risk (VaR): VaR < VaR_limit (regulatory)
- Margin requirements: collateral > minimum (exchange rules)
- Order rate limits: orders/sec < max (exchange throttling)
- Sanctioned entities: can't trade with blacklisted counterparties

**Measurable observables:**
- Order book: bid/ask prices, volumes at microsecond resolution
- Trade flow: executed trades in real-time
- Position: current holdings, real-time
- P&L: profit/loss, real-time
- Volatility: implied, realized (derived)

**Real-time requirements:**
- Market moves: microseconds to seconds
- Need <100 microsecond decision latency
- Losses can be millions per second

**Regime boundaries:**
- Normal volatility ↔ flash crash
- Liquid market ↔ thin market (low volume)
- Trending ↔ mean-reverting (different strategies)

**Transfer learning:**
- Stock A → Stock B (similar sector)
- Exchange A → Exchange B (same product, different venue)
- Yesterday → today (market patterns evolve)

### Pros:

✅ **Speed critical**: Microsecond latency = BIP FPGA advantage  
✅ **Clear constraints**: Regulatory limits, risk limits well-defined  
✅ **Excellent data**: Market data is high-frequency, precise  
✅ **High value**: HFT firms profit billions (will pay for better control)  
✅ **Fast iteration**: Can backtest on historical data immediately  
✅ **Regulatory fit**: SEC, MiFID II require pre-trade risk checks  

### Cons:

⚠️ **Weak physics**: Markets are social, not physical (no "laws")  
⚠️ **Adversarial**: Other traders adapt (not stationary environment)  
⚠️ **Ψ incomplete**: Can't measure "true value" (prices are emergent)  
⚠️ **Ethics**: HFT is controversial (does it serve society?)  
⚠️ **Competition**: Secretive industry (hard to publish/collaborate)  

### Deployment Pathway:

**Year 1**: Backtesting (historical market data)  
**Year 2**: Paper trading (live market, simulated execution)  
**Year 3**: Small capital deployment (HFT firm pilot)  
**Year 4-5**: Scale up if profitable  

### Market Size: $10B+ (HFT industry)

---

## Summary Ranking Table

| Rank | Domain | Fit | Impact | Feas | Total | Why Top Tier |
|------|--------|-----|--------|------|-------|--------------|
| 1 | **Tokamak Fusion** | 10 | 10 | 8 | **28** | Perfect fit, Nobel potential, ITER timeline |
| 2 | **Chemical Reactors** | 9 | 9 | 9 | **27** | Safety-critical, mature sensors, fast validation |
| 3 | **Spacecraft Control** | 9 | 8 | 9 | **26** | Well-defined physics, excellent sensors |
| 3 | **Power Grid** | 9 | 10 | 7 | **26** | Critical infrastructure, real-time essential |
| 5 | **Insulin Pumps** | 9 | 9 | 7 | **25** | Life-critical, clear constraints, FDA path |
| 5 | **Autonomous Vehicles** | 8 | 10 | 7 | **25** | Massive impact, huge market |
| 7 | **Robotic Manipulation** | 8 | 8 | 8 | **24** | Human safety, fast dynamics |
| 7 | **Anesthesia** | 8 | 9 | 7 | **24** | Life-critical, excellent sensors |
| 9 | **Building HVAC** | 7 | 8 | 8 | **23** | Large market, low risk |
| 10 | **High-Freq Trading** | 7 | 7 | 8 | **22** | Speed advantage, regulatory fit |

---

## Strategic Recommendation

### Start with: **Tokamak Fusion (#1)**

**Why**:
1. Perfect mathematical fit
2. Existing collaboration path (PPPL, DIII-D)
3. Validates theory on hardest case
4. If successful, opens all other domains

### Next: **Chemical Reactors (#2)**

**Why**:
1. Fast validation (lab-scale in months)
2. Demonstrates generality beyond fusion
3. Large commercial market
4. Safety value is clear

### Third: **Spacecraft (#3) or Insulin Pumps (#5)**

**Spacecraft**: 
- Well-defined physics, proves theory works
- Space industry is credible (validation matters)

**Insulin Pumps**:
- High impact, clear societal benefit
- Medical devices are Nobel-adjacent (physiology prize)

---

## Domains to Avoid (For Now)

**Building HVAC**: Weak constraints (comfort, not safety), existing MPC works well

**HFT**: Ethics concerns, secretive industry, hard to publish

**Manufacturing robots**: Crowded field, existing methods adequate

---

## Bottom Line

**Theory is sound. Practical value depends on domain.**

**Best strategy**:
1. Validate on **fusion** (perfect fit, high impact)
2. Generalize to **chemical** (fast validation, commercial)
3. Expand to **spacecraft** or **medical** (credibility, Nobel path)

**If these three succeed**: Framework proven broadly useful, prizes will follow.
